Genetic alterations in key components of these pathways, such as EGFR, BRAF, KRAS, PIK3CA, and PTEN, have been well-documented in NSCLC, and our study suggests that CKS1B may play a role in modulating these alterations to drive cancer progression (McCubrey et al., 2007; Desai et al., 2014; Herbst et al., 2018; Campbell et al., 2016; Desai et al., 2016; Beigel et al., 2020; Saini et al., 2016; Bethune et al., 2010; Tan, 2020; Yuan and Cantley, 2008; Scheffler et al., 2015). This evidence concerns the gene BRAF and non-small cell lung carcinoma.